Petros Pharmaceuticals, Inc. (PTPI) is a biopharmaceutical company dedicated to expanding consumer access to essential medications through innovative over-the-counter (OTC) drug development programs. The company’s primary focus is on transitioning its flagship prescription erectile dysfunction (ED) drug, STENDRA® (avanafil), to an OTC product – a groundbreaking endeavor that could disrupt the ED treatment landscape.
Business Overview and History
Petros Pharmaceuticals was incorporated in Delaware on May 14, 2020, with the purpose of effecting transactions contemplated by the Agreement and Plan of Merger with Neurotrope, Inc., Metuchen Pharmaceuticals LLC, and certain subsidiaries. The company consists of wholly owned subsidiaries Metuchen, Neurotrope, Timm Medical Technologies, Inc., and Pos-T-Vac, LLC.
Petros’ journey began in September 2016 when it entered into a licensing agreement with Vivus, Inc. to purchase the rights for STENDRA’s commercialization and development in the U.S. and select international markets for a one-time fee of $70 million. Under the license agreement, Petros has the exclusive right to sell STENDRA in the U.S. and its territories, as well as Canada, South America, and India.
In addition to STENDRA, Petros markets its own line of erectile dysfunction products in the form of vacuum erection device products through its subsidiaries Timm Medical and PTV. This diversification in the ED treatment space complements the company’s primary focus on STENDRA.
Since its inception, Petros has experienced net losses and negative cash flows from operations. As of December 31, 2023, the company had cash of $13.34 million, negative working capital of $9.62 million, and an accumulated deficit of $98.89 million. The company’s principal sources of capital to fund operations have been revenues from product sales, private sales, registered offerings, and private placements of equity securities.
In January 2022, Petros entered into a Settlement Agreement with Vivus related to minimum purchase requirements and returned goods. As part of this agreement, Petros executed a $10.2 million promissory note in favor of Vivus, secured by STENDRA API and products as well as Petros’ rights under the license agreement. This strategic move strengthened Petros’ balance sheet and provided the necessary resources to accelerate its OTC development efforts.
Financial Performance and Liquidity
Petros Pharmaceuticals reported net sales of $4.39 million for the nine months ended September 30, 2024, a decrease of 29% compared to the same period in 2023. This decline was primarily driven by decreased wholesaler sales of STENDRA due to reduced demand and promotional activities. Gross profit for the nine-month period was $3.44 million, representing a gross margin of 78%.
The company’s operating expenses for the nine months ended September 30, 2024, totaled $11.99 million, with the majority of the expense attributable to selling, general, and administrative costs, as well as research and development activities related to the STENDRA OTC program.
For the full fiscal year 2023, Petros reported revenue of $5.82 million and a net loss of $8.16 million. The company’s operating cash flow (OCF) and free cash flow (FCF) for 2023 were both negative $7.63 million.
In the most recent quarter (Q3 2024), Petros generated revenue of $1.58 million, a 5.99% decrease compared to Q3 2023. The net loss for Q3 2024 was $2.22 million, representing a 51.21% increase in losses year-over-year. OCF for the quarter was negative $771,250, while FCF was negative $790,380. The decreases in revenue and net income were primarily attributed to lower STENDRA sales and related sales allowances stemming from a reduction in promotional activities.
As of September 30, 2024, Petros had $3.89 million in cash and cash equivalents, with a negative working capital position of $1.80 million. The company’s total debt stood at $7.25 million, primarily consisting of a promissory note issued to Vivus in connection with the 2022 Settlement Agreement.
Petros’ liquidity position remains a significant concern, as the company does not currently have sufficient available funds to sustain operations for the next 12 months. Management has stated that it is actively exploring various financing strategies, including secured or unsecured debt, convertible debt, and equity offerings, to bolster its financial resources.
Key financial ratios as of September 30, 2024, include: – Debt/Equity ratio: 2.33 – Current ratio: 0.85 – Quick ratio: 0.74
These ratios indicate a challenging liquidity position and a high level of leverage for the company.
Prescription-to-OTC Transition Efforts
Petros’ primary focus is on transitioning STENDRA from a prescription-only medication to an over-the-counter product, a process that requires extensive collaboration with the FDA and the successful completion of a series of pivotal studies.
In 2024, the company reported positive results from an initial cohort of its self-selection study, which demonstrated that more than 78% of subjects utilizing Petros’ proprietary web-based technology application correctly self-selected to use STENDRA, compared to 56% of subjects who relied solely on the drug facts label. These encouraging findings underscore the potential benefits of the technology-assisted approach in facilitating consumer access and appropriate use of the medication.
Petros has also made significant progress in its human factors study, which aims to assess the usability and effectiveness of the technology component developed to support the STENDRA OTC transition. The successful completion of this study represents a crucial milestone in the company’s overall OTC development program.
Furthermore, Petros has proactively engaged with the FDA, securing two upcoming meetings to review the progress of its STENDRA OTC efforts and discuss the path forward. These discussions are expected to provide valuable guidance and feedback from the regulatory agency as Petros continues to navigate the complex Rx-to-OTC switch process.
Business Segments and Geographic Markets
Petros Pharmaceuticals operates through two primary business segments: Prescription Medications and Medical Devices.
The Prescription Medications segment, which consists primarily of STENDRA sales, generated $2.09 million in net sales for the nine months ended September 30, 2024, accounting for approximately 48% of the company’s total net sales. This segment achieved a gross profit of $1.89 million, or 90% of net sales, reflecting the typically higher margins associated with pharmaceutical products.
The Medical Devices segment focuses on the company’s sales of men’s health products for the treatment of ED, which do not require a prescription. This includes vacuum erection devices (VEDs) and related accessories sold both domestically and internationally. For the nine months ended September 30, 2024, the Medical Devices segment generated $2.30 million in net sales, representing 52% of Petros’ total net sales. The segment’s gross profit was $1.55 million, or 67% of net sales.
In terms of geographic markets, Petros primarily sells its products in the United States. No individual country other than the US accounted for 10% of total sales in the last reported quarter or fiscal year.
Risks and Challenges
Petros Pharmaceuticals faces several key risks and challenges that could impact its ability to successfully transition STENDRA to an OTC product:
Financing Constraints: The company’s limited financial resources and negative working capital position pose a significant risk to its ability to sustain operations and fund the ongoing OTC development efforts. Failure to secure additional funding could jeopardize the entire STENDRA OTC program.
Competition and Market Dynamics: The ED treatment landscape is highly competitive, and the introduction of an OTC PDE-5 inhibitor could face resistance from incumbent prescription medications. Petros must effectively navigate this competitive environment and demonstrate the unique value proposition of its technology-enabled OTC offering.
Execution Risks: The successful completion of the pivotal studies, the integration of the technology component, and the overall execution of the OTC transition plan all carry inherent risks that could delay or derail the company’s efforts.
Despite these challenges, Petros Pharmaceuticals remains committed to its mission of expanding consumer access to essential medications through innovative OTC solutions. The potential rewards of becoming the first company to successfully transition a PDE-5 inhibitor to an OTC product could be transformative for the company and the broader ED treatment landscape.
Conclusion
Petros Pharmaceuticals’ pursuit of making STENDRA the first OTC PDE-5 inhibitor is a bold and ambitious undertaking that could redefine the way consumers access and manage erectile dysfunction. While the company faces significant regulatory hurdles, financing constraints, and competitive pressures, its technology-driven approach and strategic collaborations with the FDA demonstrate a determined effort to navigate this complex landscape.
As Petros continues to advance its OTC development program, investors will closely monitor the company’s ability to secure the necessary funding, maintain regulatory alignment, and execute on its strategic initiatives. The successful transition of STENDRA to an OTC product could be a game-changing achievement for Petros Pharmaceuticals, with the potential to unlock new avenues for growth and solidify the company’s position as a leader in the self-care medication market.
The company’s financial performance, particularly the recent declines in revenue and increased net losses, underscores the importance of successfully executing its OTC transition strategy. With its current liquidity position and negative working capital, Petros will need to carefully manage its resources and potentially secure additional funding to support its ongoing operations and development efforts.
The diversification of Petros’ business through its Medical Devices segment provides some stability to the company’s revenue stream, but the success of the STENDRA OTC program remains crucial for the company’s long-term growth prospects. As Petros continues to navigate the challenges ahead, stakeholders will be watching closely for progress in its regulatory discussions, study results, and financial performance in the coming quarters.
Disclaimer: This article is for informational purposes only. It does not constitute financial, legal, or other types of advice. While every effort has been made to ensure the accuracy of the information presented here, the author and the publisher do not make any guarantees about the completeness, reliability, and accuracy of this information.